Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
Oligomeric forms of alpha-synuclein are emerging as key mediators of pathogenesis in Parkinson's disease. Our understanding of the exact contribution of alpha-synuclein oligomers to disease is limited by the lack of a technique for their specific detection. We describe a novel method, the alpha-synuclein proximity ligation assay, which specifically recognizes alpha-synuclein oligomers. In a blinded study with post-mortem brain tissue from patients with Parkinson's disease (n = 8, age range 73-92 years, four males and four females) and age- and sex-matched controls (n = 8), we show that the alpha-synuclein proximity ligation assay reveals previously unrecognized pathology in the form of extensive diffuse deposition of alpha-synuclein oligomers. These oligomers are often localized, in the absence of Lewy bodies, to neuroanatomical regions mildly affected in Parkinson's disease. Diffuse alpha-synuclein proximity ligation assay signal is significantly more abundant in patients compared to controls in regions including the cingulate cortex (1.6-fold increase) and the reticular formation of the medulla (6.5-fold increase). In addition, the alpha-synuclein proximity ligation assay labels very early perikaryal aggregates in morphologically intact neurons that may precede the development of classical Parkinson's disease lesions, such as pale bodies or Lewy bodies. Furthermore, the alpha-synuclein proximity ligation assay preferentially detects early-stage, loosely compacted lesions such as pale bodies in patient tissue, whereas Lewy bodies, considered heavily compacted late lesions are only very exceptionally stained. The alpha-synuclein proximity ligation assay preferentially labels alpha-synuclein oligomers produced in vitro compared to monomers and fibrils, while stained oligomers in human brain display a distinct intermediate proteinase K resistance, suggesting the detection of a conformer that is different from both physiological, presynaptic alpha-synuclein (proteinase K-sensitive) and highly aggregated alpha-synuclein within Lewy bodies (proteinase K-resistant). These disease-associated conformers represent previously undetected Parkinson's disease pathology uncovered by the alpha-synuclein proximity ligation assay.
1 Department of Physiology, Anatomy and Genetics, University of Oxford, Le Gros Clark Building, South Parks Road, Oxford OX1 3QX, UK 2 Oxford Parkinson's Disease Centre, University of Oxford, Le Gros Clark Building, South Parks Road, Oxford, OX1 3QX, UK.
Rosalind F
RF
Roberts
1 Department of Physiology, Anatomy and Genetics, University of Oxford, Le Gros Clark Building, South Parks Road, Oxford OX1 3QX, UK 2 Oxford Parkinson's Disease Centre, University of Oxford, Le Gros Clark Building, South Parks Road, Oxford, OX1 3QX, UK javier.alegre@dpag.ox.ac.uk richard.wade-martins@dpag.ox.ac.uk.
Richard
R
Wade-Martins
1 Department of Physiology, Anatomy and Genetics, University of Oxford, Le Gros Clark Building, South Parks Road, Oxford OX1 3QX, UK 2 Oxford Parkinson's Disease Centre, University of Oxford, Le Gros Clark Building, South Parks Road, Oxford, OX1 3QX, UK javier.alegre@dpag.ox.ac.uk richard.wade-martins@dpag.ox.ac.uk.
Javier
J
Alegre-Abarrategui
D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D042241:Early Diagnosis; D005260:Female; D005455:Fluorescent Antibody Technique; D006179:Gyrus Cinguli / Q000378:metabolism* / Q000473:pathology; D057809:HEK293 Cells; D006801:Humans; D016631:Lewy Bodies / Q000378:metabolism / Q000473:pathology; D008297:Male; D009474:Neurons / Q000378:metabolism; D010300:Parkinson Disease / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology*; D058105:Polymerization; D012154:Reticular Formation / Q000378:metabolism* / Q000473:pathology; D051844:alpha-Synuclein / Q000737:chemistry / Q000378:metabolism*
D051844:alpha-Synuclein
Parkinson’s disease; alpha-synuclein; oligomers; pathology